M-Scan Ltd Successfully Passes GMP Inspections by the FDA and UK MHRA

Wokingham, United Kingdom, July 04, 2008 --(PR.com)-- Another of the laboratories within the M-Scan group, M-Scan Ltd (Wokingham, UK), has successfully completed regulatory inspections conducted by both the United States FDA and the UK MHRA. M-Scan Ltd, which has been fully compliant with GLP since 1992, now joins the other M-Scan labs in offering analytical services throughout the clinical development phases of drug discovery. In a new initiative, the MHRA has introduced a “certificate of GMP inspection” and M-Scan Ltd will be amongst the first laboratories to receive this. Please contact M-Scan Ltd for a copy.

M-Scan provides specialised mass spectrometry and related services for the characterisation of pharmaceuticals and biotech products. Studies involve recombinant and native molecules at all stages of the product development pipeline, including research (Proteomics), process QC, bioanalysis and regulatory approval. Structural analysis services are tailored to the requirements of the FDA “well-characterized” or “specified” molecule definition and a full analysis package is provided for characterisation under the ICH Q6B guidelines.

The four laboratories in the M-Scan Group (UK, Switzerland, Germany, and the States) are equipped with over 25 mass spectrometers, providing a range of ionisation and detection techniques for optimum sensitivity and versatility. The labs are supported by offices in UK, Germany, S. Korea, Singapore and India.

###